drugset / Trial / NCT00052377

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

NCT00052377

Phase 1/2 Terminated 46 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I/II trial to study the effectiveness of combining interleukin-12 with interleukin-2 in treating patients who have mycosis fungoides. Biological therapies, such as interleukin-12 and interleukin-2, use different ways to stimulate the immune system and stop cancer cells from growing. Combining more than one biological therapy may kill more tumor cells

Timeline

Start
2002-09
Primary completion
2005-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Subcutaneous
Subject interleukin-12 Protein / enzyme biologic Subcutaneous